Equity Overview
Price & Market Data
Price: $25.30
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $725,473,152
Daily Volume: 0
Performance Metrics
1 Week: 8.82%
1 Month: 6.39%
3 Months: 23.05%
6 Months: 68.11%
1 Year: 33.16%
YTD: 13.66%
Company Details
Employees: 27
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.